Intranasal adenovirus-5 influenza vaccine
Intranasal administration of a replication defective adenoviral vector addresses the need for comprehensive immune responses by stimulating systemic and mucosal immunity, effectively protecting against influenza and cancer.
Patent Information
- Application Number
- PCT/US2026/027409
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing vaccination strategies fail to generate robust and comprehensive immune responses, particularly at mucosal surfaces, necessitating improved methods for inducing antigen-specific immune responses to enhance protection against respiratory pathogens and certain cancers.
Intranasal administration of a replication defective adenoviral vector, engineered with deletions in the E2b and/or El regions, encoding target antigens to stimulate systemic and mucosal antigen-specific immune responses, including IgG, IgA antibodies, CD8+ T cells, and B cells.
Generates robust systemic and mucosal immune responses, effectively protecting against influenza strains and potentially inhibiting contagion, with the potential to treat influenza and enhance cancer immunity.
Smart Images

Figure US2026027409_12112026_PF_FP_ABST
Abstract
Description
Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01INTRANASAL ADENOVIRUS-5 INFLUENZA VACCINE CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Pat. Application No. 63 / 802,774, filed 9 May 2025, the entire contents of which are incorporated herein by reference.FIELD
[0002] The present disclosure concerns compositions and methods for stimulating immune responses in a subject by administering, intranasally, replication defective adenoviral vectors. BACKGROUND
[0003] U.S. Patent No. 9,248,177 (UAB Research Foundation) describes non-replicating adenoviral vectors that contain and express one or more influenza antigens or epitopes to a mucosal region of a mammal to non-invasively inducing a protective immune response against influenza.
[0004] Respiratory infections — including influenza — continue to present significant public health challenges worldwide. While conventional vaccination strategies have shown efficacy in preventing certain diseases, there remains a need for improved methods that generate robust and comprehensive immune responses, particularly at mucosal surfaces where pathogens initially encounter the host. Specifically, there exists a need for methods of inducing comprehensive antigen-specific immune responses through a targeted delivery approach that may enhance protection against respiratory pathogens and potentially certain cancers.SUMMARY|0005| The present disclosure provides methods of stimulating an antigen-specific immune response in a subject through intranasal administration of a replication defective adenoviral vector.
[0006] In some aspects, the present disclosure provides a method of stimulating an antigenspecific immune response in a subject in need thereof. In some aspects, the method may includeNant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 intranasally administering, to the subject, a replication defective adenoviral vector. In some aspects, the replication defective adenoviral vector may include a deletion in the E2b region; and a nucleic acid sequence encoding one or more target antigens. In some aspects, the one or more target antigens may include infectious disease-associated proteins. In some aspects, the target antigens may include cancer-associated proteins. In some aspects, the replication defective adenovirus vector may include a deletion in the El region.
[0007] In some aspects, the method may generate systemic and mucosal antigen-specific IgG and IgA antibodies. In some aspects, the method may generate systemic and mucosal antigen-specific CD8+ T cells. In some aspects, the method may generate systemic and mucosal antigen-specific B cells. In some aspects, the antigen-specific B cells may be generated in one or more locations selected from the group consisting of the mediastinal lymph nodes (MedLN), lungs, and / or bronchoalveolar lavage (BAL). In some aspects, the antigen-specific B cells may be generated in the lungs.
[0008] In some aspects, the antigen-specific IgG and IgA may be generated in the lungs. In some aspects, the antigen-specific tissue resident T-bet+ memory B cells may be generated in the lungs, the BAL, or both.
[0009] In some aspects, the present disclosure provides a method of stimulating mucosal immunity in the upper respiratory tract (URT) in a subject in need thereof. In some aspects, the method may include intranasally administering to the subject a replication defective adenoviral vector. In some aspects, the replication defective adenoviral vector may include a deletion in the E2b region and a nucleic acid sequence encoding one or more target antigens. In some aspects, the one or more target antigens may include infectious disease-associated proteins. In some aspects, the one or more target antigens may include cancer-associated proteins.
[0010] In some aspects, the one or more target antigens may include influenza virus-associated proteins. In some aspects, the method may generate IgG and IgA antibodies that bind to presentNant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 influenza strains, past influenza strains, and potential pandemic influenza strains. In some aspects, the influenza strain may be PR8.
[0011] In some aspects, the present disclosure provides a method of treating influenza in a subject in need thereof. In some aspects, the method may include intranasally administering, to the subject, a replication defective adenoviral vector. In some aspects, the replication defective adenoviral vector may include a deletion in the E2b region and a nucleic acid sequence encoding one or more target antigens. In some aspects, the one or more target antigens may include influenza virus-associated proteins.
[0012] In some aspects, the present disclosure provides a method of inhibiting contagion of influenza in a population of subjects. In some aspects, the method may include intranasally administering, to at least one subject in the population, a vaccine comprising a replication defective adenoviral vector. In some aspects, the replication defective adenoviral vector may include a deletion in the E2b region and a nucleic acid sequence encoding one or more target antigens. In some aspects, the one or more target antigens may include influenza virus-associated proteins. In some aspects, the method may protect unvaccinated subjects in the population from influenza virus transmission.BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 is a schema of experiments for testing intranasal administration of the Ad5-NP or Ad5-HA vaccine in vivo in mice.
[0014] FIG. 2 is an exemplary flow diagram of a mediastinal lymph node (MedLN) gating strategy at day 21 post-vaccination in HA(+) mice.
[0015] FIG. 3 is an exemplary flow diagram of a mediastinal lymph node (MedLN) gating strategy at day 21 post- vaccination in NP(+) mice.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0016] FIG. 4 shows total HA+ memory B-cells on the left and total HA+ germinal center B-cells (GCB) at 21 days post vaccination. The top graph in each column shows data for animals immunized with Ad5-HA. The bottom graph in each column shows data for animals immunized with Ad5-NP.
[0017] FIG. 5 shows IgG antibodies specific to the target antigen detected in the BAL, serum, nasal wash, and nasal swab in samples taken 28 days post-vaccination. The top graph in each column shows data for animals immunized with Ad5-HA. The bottom graph in each column shows data for animals immunized with Ad5-NP.
[0018] FIG. 6 shows IgA antibodies specific to the target antigen detected in the BAL, serum, nasal wash, and nasal swab in samples taken 28 days post-vaccination. The top graph in each column shows data for animals immunized with Ad5-HA. The bottom graph in each column shows data for animals immunized with Ad5-NP.
[0019] FIG. 7 shows exemplary flow diagrams of a T-cell lung gating strategy at day 21 postvaccination in CD8a and CD3.
[0020] FIG. 8 shows exemplary flow diagrams of a T-cell MedLN gating strategy at day 21 postvaccination in CD8a and CD3.
[0021] FIG. 9 shows exemplary flow diagrams of a T-cell BAL gating strategy at day 21 postvaccination in CD8a and CD3.
[0022] FIG. 10A shows total NP+ CD8+ CD3+ T-cells in the lungs following intranasal immunization with the Ad5-HA and Ad5-NP vaccine generating T-cells specific to the target antigen, with samples taken 21 days post-vaccination. FIG. 10B shows total NP+ CD8+ CD3+ T-cells in the MedLN following intranasal immunization with the Ad5-HA and Ad5-NP vaccine generating T-cells specific to the target antigen, with samples taken 21 days post-vaccination. FIG.10C shows total NP+ CD8+ CD3+ T-cells in the BAL following intranasal immunization with theNant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 Ad5-HA and Ad5-NP vaccine generating T-cells specific to the target antigen, with samples taken 21 days post-vaccination.
[0023] FIG. 11 is a schematic of an experimental design for testing antigen-specific B-cell development following primary vaccination with Ad5-HA in mice.
[0024] FIG. 12A shows results of intranasal immunization with the Ad5-HA vaccine at generating antigen-specific B-cells in the lungs as early as 14 days post-vaccination. FIG. 12B shows results of intranasal immunization with the Ad5-HA vaccine at generating antigen-specific B-cells in the MedLN lungs as early as 14 days post -vaccination. FIG. 12C shows results of intranasal immunization with the Ad5-HA vaccine at generating antigen-specific B-cells in the BAL as early as 14 days post-vaccination. The lower data series indicates vehicle administration. The upper data series indicates Ad5-HA administration. The grey data points indicate UI administration.
[0025] FIG. 13 is a schema of experiments for characterization of antigen-specific tissue resident B-cells following primary vaccination with Ad5-HA in mice.
[0026] FIG. 14A shows exemplary flow diagrams of a lung gating strategy at day 28 postvaccination in T-bet reporter mice. FIG. 14B shows exemplary flow diagrams of a BAL gating strategy at day 28 post-vaccination in T-bet reporter mice.
[0027] FIG. 15 shows results of intranasal immunization with the Ad5-HA vaccine generating antigen-specific tissue resident B-cells in the lungs and BAL, with samples taken 28 days postvaccination. Lung tissues were gated using CD 19+ IgD-.
[0028] FIG. 16 is a schema of experiments for testing the efficacy of vaccination intraperitoneally (i.p.) compared to intranasally (i.n.) in mice.
[0029] FIG. 17 shows results of intranasal immunization with the Ad5-HA vaccine generating B-cells in the lungs, MedLN, and BAL, with samples taken 33 days post-vaccination. Lung tissues were gated using CD 19+ IgD-.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0030] FIG. 18 is a schema experiments for CBA analysis of nasal swab (NS), BAL, and serum collected 30 days post-primary vaccination, comparing intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) administration in mice.
[0031] FIG. 19A shows IgA data from intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) immunization with the Ad5-HA vaccine with regards to vaccine antigen CA2009 (H1N1). FIG. 19B shows IgG data from intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) immunization with the Ad5-HA vaccine with regards to vaccine antigen CA2009 (H1N1).
[0032] FIG. 20A shows IgA data from intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) immunization with the Ad5-HA vaccine with regards to related seasonal HA (hemagglutinin) WI2022 (H1N1). FIG. 20B shows IgG data from intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) immunization with the Ad5-HA vaccine with regards to related seasonal HA (hemagglutinin) WI2022 (H1N1).
[0033] FIG. 21A shows IgA data from intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) immunization with the Ad5-HA vaccine with regards to related seasonal HA BB2018 (H1N1). FIG. 21B shows IgG data from intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) immunization with the Ad5-HA vaccine with regards to related seasonal HA BB2018 (H1N1).
[0034] FIG. 22A shows IgA data from intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) immunization with the Ad5-HA vaccine with regards to distally related pandemic HA PR8-1934 (H1N1). FIG. 22B shows IgG data from intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) immunization with the Ad5-HA vaccine with regards to distally related pandemic HA PR8-1934 (H1N1).
[0035] FIG. 23 is a map showing potential influenza pandemic strains, grouped by Group 1 and Group 2.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0036] FIG. 24A shows IgA data from intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) immunization with the Ad5-HA vaccine with regards to avian H5N1 (VN2004). FIG. 24B shows IgG data from intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) immunization with the Ad5-HA vaccine with regards to avian H5N1 (VN2004).
[0037] FIG. 25A shows IgA data from intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) immunization with the Ad5-HA vaccine with regards to avian H2N9 (NL1999). FIG. 25B shows IgG data from intraperitoneal (i.p.), intranasal (i.n.), and intramuscular (i.m.) immunization with the Ad5-HA vaccine with regards to avian H2N9 (NL1999).
[0038] FIG. 26 is a schema of experiments for CBA analysis of nasal swabs (NS) following Ad5-HA vaccination compared to infection with influenza strain CA09 in mice.
[0039] FIG. 27A shows median fluorescence intensity (MFI) in anti-HA IgA for CA2009 (H1N1) for i.n. Ad5 CA09 HA administration and i.m. Ad5 CA09 HA administration as compared to vehicle. FIG. 27B shows MFI in anti-HA IgA for CA2009 (H1N1) for i.n. CA09 infection as compared to vehicle.
[0040] FIG. 28A shows MFI in anti-HA IgA for seasonal related Ag Hl (WI2022) for i.n. Ad5 CA09 HA administration and i.m. Ad5 CA09 HA administration as compared to vehicle. FIG.28B shows MFI in anti-HA IgA for seasonal related Ag Hl (WI2022) for i.n. CA09 infection as compared to vehicle.
[0041] FIG. 29A shows MFI in anti-HA IgA for seasonal related Ag Hl (BB2018) for i.n. Ad5 CA09 HA administration and i.m. Ad5 CA09 HA administration as compared to vehicle. FIG.29B shows MFI in anti-HA IgA for seasonal related Ag Hl (BB2018) for i.n. CA09 infection as compared to vehicle.
[0042] FIG. 30A shows MFI in anti-HA IgA for distally related pandemic Hl Ag (PR8-1934) for i.n. Ad5 CA09 HA administration and i.m. Ad5 CA09 HA administration as compared toNant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 vehicle. FIG. 30B shows MFI in anti-HA IgA for distally related pandemic Hl Ag (PR8-1934) for i.n. CA09 infection as compared to vehicle.
[0043] FIG. 31 is a schema of experiments for testing the efficiency of intranasal Ad5 vaccination following Pr8 exposure in mice.
[0044] FIG. 32 is a graph showing body weight (as a % of day 0) compared to time (as days postinfection) for vaccinated mice against PR8 induced morbidity.
[0045] FIG. 33 a schema of experiments for testing the efficiency of vaccines against live CA09 infection in hamster models.
[0046] FIG. 34 is a graph showing antigen-specific IgG development. MFI-anti-HA IgG generation is shown in post-vaccination (left) and post-infection (right) hamsters.
[0047] FIG. 35 is a graph showing antigen-specific IgA development. MFI-anti-HA IgG generation is shown in post-vaccination (left) and post-infection (right) hamsters.
[0048] FIG. 36 is a graph showing body weight (as a % of day 0) compared to time (as days postinfection) for vaccinated hamsters against CA09 induced morbidity.
[0049] FIG. 37 is a schema of experiments for testing the efficacy of the Ad5-HA vaccine in blocking transmission in vivo using a hamster model.
[0050] FIG. 38A shows antigen-specific IgG and IgA development in response to a related Hl (CA2009) in hamsters, anti-HA IgA MFI generation post-prime (left) and post-boost (right). FIG.38B shows antigen-specific IgG and IgA development in response to a related Hl (CA2009) in hamsters, anti-HA IgG MFI generation post-prime (left) and post-boost (right).
[0051] FIG. 39A shows antigen-specific IgG and IgA development in response to a vaccine Hl (WI2022) in hamsters, anti-HA IgA MFI generation post-prime (left) and post-boost (right). FIG.39B shows antigen-specific IgG and IgA development in response to a vaccine Hl (WI2022) in hamsters, anti-HA IgG MFI generation post-prime (left) and post-boost (right).Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0052] FIG. 40A shows antigen-specific IgG and IgA development in response to a related Hl (BB2018) in hamsters, anti-HA IgA MFI generation post-prime (left) and post-boost (right). FIG.40B shows antigen-specific IgG and IgA development in response to a related Hl (BB2018) in hamsters, anti-HA IgG MFI generation post-prime (left) and post-boost (right).
[0053] FIG. 41A shows antigen-specific IgG and IgA development in response to a distally related pandemic Hl (PR8-1934) in hamsters, anti-HA IgA MFI generation post-prime (left) and post-boost (right). FIG. 41 B shows antigen-specific IgG and IgA development in response to a distally related pandemic Hl (PR8-1934) in hamsters, anti-HA IgG MFI generation post-prime (left) and post-boost (right).
[0054] FIG. 42A shows body weight for vaccinated hamsters (as a % of day 0) compared to time (as days post-infection) for hamsters against homotypic challenge infection (CA09) induced morbidity. FIG. 42B shows body weight for unvaccinated hamsters (as a % of day 0) compared to time (as days post-infection) for hamsters against homotypic challenge infection (CA09) induced morbidity.
[0055] FIG. 43 shows representative flow cytometry gating strategies for identification of CA09HA+B cell populations in the mediastinal lymph node (MedLN), lung, and bronchial alveolar lavage (BAL) following intranasal immunization with CA09HA Ad5 orEmpty-Ad5. FIG.43 A shows identification of CD138+CD19+ / 1° CA09HA+plasmablasts in the MedLN at day 7 postimmunization, gated on live, Dumpneg(CD64“CD3“) cells. FIG. 43B shows identification of CD38+PNAlo CA09HA+ memory B cells and CD381oPNA+ germinal center B cells in the MedLN at day 21 post-immunization. FIG. 43C shows identification of CD38+CD95+CA09HA+memory B cells and CD38loCD95+germinal center B cells in the lung at day 21 postimmunization. FIG. 43D shows identification of CD38+CD95+CA09HA+memory B cells in the BAL at day 28 post-immunization. Frequencies are reported as mean ± SD.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117WO1
[0056] FIG. 44 shows results of intranasal immunization with CA09HA-A45 generating CA09HA-specific B cell and antibody responses. FIGs. 44A-C show CA09HA+plasmablasts at day 7 and CA09HA+memory and germinal center B cells at day 21 in the MedLN. FIGs. 44D-H show CA09HA+memory B cells and germinal center B cells in the MedLN, lung, and BAL from day 0 to day 28 post-immunization. FIGs. 441 & 44J show CA09HA-specific IgG and IgA detected in serum, BAL, nasal wash, and nasal swab at day 30 post-immunization.
[0057] FIG. 45 shows results of intranasal immunization with NP-Ad5 generating NP-specific B cell and antibody responses. FIGs. 45A & B show gating strategies to identify NP+ plasmablasts at day 7 and NP+ memory and germinal center B cells at day 21 in the MedLN. FIGs. 45C-E show NP+plasmablasts at day 7 and NP+memory and germinal center B cells at day 21 in the MedLN. FIGs. 45F & G show NP-specific IgA and IgG detected in serum, BAL, nasal wash, and nasal swab at day 28 post-immunization.
[0058] FIG. 46 shows results of intranasal immunization with CA09HA-Ad5 generating CA09HA+Tbx21+memory B cells in the lung and BAL at day 28 post-immunization. FIGs. 46A, D show representative gating strategies, and FIGs. 46B, C, E, & F show frequencies and numbers of CA09HA+Tbx21+memory B cells in lung and BAL.
[0059] FIG. 47 shows results comparing intranasal and intraperitoneal immunization with NP-Ad5 or CA09HA-Ad5 in generating humoral immune responses. MedLN and lung tissues were analyzed by flow cytometry at day 28 or day 30 post-immunization. Seram, BAL, nasal wash, and nasal swab samples were collected at day 30 and analyzed by CBA, with additional nasal swab samples collected post-boost.|0060| FIG. 48 shows representative flow cytometry gating strategies identifying NP-specific CD8+ T cell subsets and CA09HA+ B cell subsets in the MedLN and lung following intranasal or intraperitoneal immunization. FIGs. 48A & B show identification of NP-specific CD69+CD103+ CD8+ T cells and related subsets at day 28 post-immunization. FIGS. 48C & D show identificationNant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 of CA09HA+ memory and germinal center B cells in lung and MedLN at day 30 postimmunization.
[0061] FIG. 49 shows results of intranasal immunization with NP-Ad5 generating NP-specihc CD8+T cell responses. FIGs. 49A-C show gating strategies for NP-specihc CD8+T cells in MedLN, lung, and BAL at day 21 post-immunization. FIGs. 49D-F show NP-specihc CD8+T cells in MedLN, lung, and BAL from day 0 to day 28 post-immunization.
[0062] FIG. 50 shows results of intranasal immunization with CA09HA Ad5 generating broadly reactive antibody responses. FIGs. 50B-Q show antigen-specihc IgG in serum and IgA in BAL, nasal wash, and nasal swab against multiple Hl HA antigens at day 30 post-immunization or following infection.
[0063] FIG. 51 shows results of intranasal immunization with CA09HA-Ad5 generating broadly reactive IgG responses to Hl HA antigens. FIGs. 51A-L show antigen-specihc IgG detected in BAL, nasal wash, and nasal swab samples.
[0064] FIG. 52 shows results of intranasal immunization with CA09HA-Ad5 followed by heterologous viral challenge. FIGs. 52B & C show antigen-specihc IgA in nasal swab samples post-boost. FIGs. 52D & E show viral burden in nasal wash and lung. FIG. 52F shows body weight over time. FIGs. 52G & H show representative lung histology. FIGs. 52I-M show lung pathology scoring.
[0065] FIG. 53 shows results of intranasal immunization of hamsters with CA09HA-Ad5 followed by viral challenge. FIGs. 53B & C show serum IgG post-prime and post-boost. FIGs.53D-G show nasal IgG and IgA responses. FIGs. 54H & I show viral burden in lung and nasal wash. FIG. 53J shows viral RNA in nasal swab samples. FIGs. 53K & L show antigen-specihc serum IgG post-infection.
[0066] FIG. 54 shows results of intranasal immunization of hamsters with CA09HA-Ad5 generating broadly reactive antibody responses. FIGs. 54A-R show antigen-specihc IgG and IgANant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 detected in serum and nasal swab samples against multiple Hl HA antigens following prime and boost immunization.
[0067] FIG. 55 shows results of intranasal immunization of hamsters with CA09HA-Ad5 generating broadly reactive antibody responses. FIGs. 55A-G show antigen-specific IgG and IgA detected in serum and nasal swab samples against H3 DW21HA antigens following prime and boost immunization. FIGs. 55H-N show antigen-specific IgG and IgA detected in serum and nasal swab samples against H2 NL99HA antigens following prime and boost immunization. FIGs. 550 U show antigen-specific IgG and IgA detected in serum and nasal swab samples against H5 VN04HA antigens following prime and boost immunization.DETAILED DESCRIPTION
[0068] The present disclosure describes methods for stimulating an antigen-specific immune response in a subject through intranasal administration of a replication defective adenoviral vector. Various aspects may be practiced without some or all of these specific details. In certain instances, well known operations have been described in less detail so as not to obscure the embodiments.
[0069] The present disclosure provides methods of stimulating an antigen-specific immune response in a subject through intranasal administration of a replication defective adenoviral vector.
[0070] In some aspects, the present disclosure provides a method of stimulating an antigenspecific immune response in a subject in need thereof. In some aspects, the method may include intranasally administering, to the subject, a replication defective adenoviral vector. In some aspects, the replication defective adenoviral vector may include a deletion in the E2b region and a nucleic acid sequence encoding one or more target antigens. In some aspects, the one or more target antigens may include infectious disease-associated proteins. In some aspects, the target antigens may include cancer-associated proteins. In some aspects, the replication defective adenovirus vector may include a deletion in the El region.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0071] As used herein, “replication defective adenoviral vector” refers to an adenoviral vector that has been genetically modified to prevent it from replicating in target cells. As is known, the replication capabilities of adenoviral vectors can be disabled by deleting portions of the viral genome that are essential for viral replication, such as the El and / or E2b regions. In particular aspects, the adenoviral vector is an adenovirus serotype 5 (Ad5) vector, though other adenoviral serotypes may also be employed, including but not limited to Ad3, Ad4, Ad7, Adil, Adl4, Ad21, Ad35, & Ad41.
[0072] In some aspects, the replication defective adenoviral vector comprises a deletion in the E2b region, which encodes proteins required for viral DNA replication, including the viral DNA polymerase and pre-terminal protein. Deletion of this region may render the virus unable to replicate its genome. In some aspects, the deletion in the E2b region may be a partial deletion, a complete deletion, or a deletion with a substitution of heterologous genetic material.
[0073] In some aspects, the replication defective adenoviral vector further comprises a deletion in the El region, which encodes proteins involved in the regulation of transcription of the viral genome. Deletion of the El region may prevent the expression of other viral genes and renders the virus replication-defective. In some aspects, the deletion in the El region may be a partial deletion, a complete deletion, or a deletion with a substitution of heterologous genetic material.
[0074] In some aspects, the replication defective adenoviral vector may further comprise additional modifications in other regions of the viral genome, such as deletions in the E3 and / or E4 regions. In some aspects, the deletion in the E3 and / or E4 regions may be a partial deletion, a complete deletion, or a deletion with a substitution of heterologous genetic material. These additional modifications may increase the cloning capacity of the vector and / or reduce its immunogenicity.
[0075] In some aspects, the replication defective adenoviral vector may comprise a nucleic acid sequence encoding one or more target antigens. The nucleic acid sequence may be operably linkedNant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 to a promoter capable of directing expression of the target antigen(s) in mammalian cells. Suitable promoters include, but are not limited to, the cytomegalovirus (CMV) immediate-early promoter, the Rous sarcoma vims (RSV) long terminal repeat, the adenovirus major late promoter, the herpes simplex vims (HSV) thymidine kinase promoter, and tissue-specific promoters.
[0076] As used herein, “target antigen” refers to a molecule or portion thereof that is capable of eliciting an immune response in a subject. In some aspects, the target antigen may be a protein, a peptide, a carbohydrate, a lipid, or a nucleic acid. In some aspects, the target antigen may be a full-length protein or a fragment thereof comprising at least one epitope.
[0077] In some aspects, the one or more target antigens include infectious disease-associated proteins. As used herein, “infectious disease-associated proteins” refers to proteins derived from pathogenic organisms, including but not limited to viruses, bacteria, fungi, and parasites. Examples of infectious disease-associated proteins may include, but are not limited to, viral stmctural proteins, viral enzymes, viral regulatory proteins, bacterial toxins, bacterial surface proteins, fungal cell wall components, and parasite surface antigens.
[0078] In some aspects, the infectious disease-associated proteins may include influenza virus-associated proteins. As used herein, “influenza virus-associated proteins” refers to proteins derived from influenza vimses, and may include but are not limited to hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), matrix protein 1 (Ml), matrix protein 2 (M2), polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2), polymerase acidic protein (PA), and non-structural protein 1 (NS1). In some aspects, the influenza virus-associated proteins may be derived from influenza A vimses, influenza B vimses, and / or influenza C vimses.
[0079] In some aspects, the influenza vims-associated proteins may include naturally occurring variants or mutant forms thereof, including proteins that comprise one or more amino acid substitutions, deletions, or insertions relative to reference sequences. Such mutations may affect the antigenicity, immunogenicity, or functional properties of the proteins. For example, asNant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 observed with other viral pathogens such as SARS-CoV-2, mutations in viral proteins may impact viral fitness, host immune recognition, or vaccine efficacy. Accordingly, in some aspects, the influenza virus-associated proteins described herein may encompass mutated or variant forms derived from circulating or emerging strains, including but not limited to pandemic or zoonotic strains.
[0080] In some aspects, the one or more target antigens include cancer-associated proteins. As used herein, “cancer-associated proteins” refers to proteins that are preferentially expressed or overexpressed in cancer cells compared to normal cells, or proteins that are mutated or otherwise altered in cancer cells. Examples of cancer-associated proteins may include, but are not limited to, tumor-specific antigens (TSAs), tumor-associated antigens (TAAs), neoantigens, cancer-testis antigens, oncofetal antigens, oncogenic viral proteins, mutated cellular proteins, and overexpressed cellular proteins.
[0081] In some aspects, the method involves intranasal administration of the replication defective adenoviral vector to the subject. As used herein, “intranasal administration” refers to the delivery of a composition through the nostrils to the nasal cavity. Intranasal administration may be performed using various devices known in the art, including but not limited to nasal sprays, nasal drops, nasal syringes, and nasal nebulizers.
[0082] In some aspects, the method involves a single intranasal administration of the replication defective adenoviral vector. In other aspects, the method may involve multiple intranasal administrations of the replication defective adenoviral vector, separated by intervals of days, weeks, or months, for example, every day, twice per day (BID), once every other day, once every week, once every month, etc. In some aspects, the method may involve a prime-boost regimen, wherein a first dose (prime) of the replication defective adenoviral vector is administered, followed by one or more subsequent doses (boosts) of the same or a different vaccine composition. In some aspects, the administration involves the combination of more than one dosing regimen or protocol.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0083] As used herein, “subject” refers to any member of the animal kingdom, including mammals such as humans, non-human primates, rodents (e.g., mice, rats, hamsters), lagomorphs (e.g., rabbits), canines, felines, equines, bovines, ovines, porcines, caprines, ursines (e.g., polar bears), and avians. In some aspects, the subject is a human.
[0084] In some aspects, the method may generate systemic and mucosal antigen-specific IgG antibodies. In some aspects, the method may generate systemic and mucosal antigen-specific IgA antibodies. In some aspects, the method may generate systemic and mucosal antigen-specific CD8+ T cells. In some aspects, the method may generate systemic and mucosal antigen-specific B cells. In some aspects, the antigen-specific B cells may be generated in one or more locations selected from the group consisting of the MedLn, lungs, and / or BAL. In some aspects, the antigenspecific B cells may be generated in the lungs.
[0085] In some aspects, the present disclosure provides methods wherein the replication defective adenoviral vector is administered in combination with one or more immunostimulatory agents. In some aspects, the immunostimulatory agent may include an IL- 15 receptor agonist, such as N-803 (also known as ALT-803, nogapendekin alfa inbakicept, or ANKTIVA), IL-15, an IL-15:IL-15Ra complex, and / or a fusion construct derived therefrom. In some aspects, the IL-15 receptor agonist may stimulate IL-15Rf>v signaling to promote expansion and activation of CD8+ T cells and natural killer (NK) cells, thereby enhancing the cellular immune response elicited by the adenoviral vector.
[0086] In some aspects, the immunostimulatory agent, such as N-803, IL-15, and / or an IL-15JL-15Ra complex may be encoded by an adenoviral vector. In some aspects, the adenoviral vector encoding the immunostimulatory agent may be the same vector as the replication defective adenoviral vector (that is, the vector that encodes the immunogenic sequences). In some aspects, the immunostimulatory agent may be encoded by a second adenoviral vector that is distinct from the replication defective adenoviral vector. In some aspects, the adenoviral vector encoding theNant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 immunostimulatory agent may be Co-administered intranasally with the replication defective adenoviral vector. In some aspects, the adenoviral vector encoding the immunostimulatory agent may be administered separately from the replication defective adenoviral vector, such as by intravenous injection.
[0087] In some aspects, the present disclosure provides methods wherein the replication defective adenoviral vector is administered in combination with a toll-like receptor (TLR) agonist. In particular aspects, the TLR agonist may include 3M-052-AF, a synthetic TLR7 / 8 agonist formulated in an aqueous formulation. In some aspects, 3M-052-AF may enhance local innate immune activation and support the generation of robust antigen-specific adaptive immune responses. In some aspects, the replication defective adenoviral vector is administered in combination with 3M-052-AF as part of a combination immunotherapy regimen, as described in Lykins et al. (2024) “Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization” Front. Immunol. 15:1480976. In some aspects, TLR agonists may exhibit structural or functional similarity to naturally occurring immunostimulatory molecules, such as single-stranded RNA or other viral pathogen-associated molecular patterns, thereby mimical natural infection and promoting a desirable immune profile.
[0088] In some aspects, the one or more immunostimulatory agents may include cellular or biologic agents such as targeting high-affinity NK (t-haNK) cells, including PD-L1 t-haNK, intratumorally administered yeast, checkpoint inhibitor antibodies, memory-like cytokine-enhanced NK (m-ceNK) cells, and / or lysed NK-92 cells. U.S. Published Application 2024 / 0016849 (the entire contents of which are herein incorporated by reference) explains that t-haNK cells are genetically engineered NK cells expressing high-affinity CD 16 and a chimeric antigen receptor (CAR). In some aspects, t-haNK cells may enhance antibody-dependent cellular cytotoxicity (ADCC) and directly target infected cells or tumor cells, thereby promoting a moreNant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 effective immune response in conjunction with the adenoviral vector. In some aspects, intratumoral yeast (whole yeast and / or a lysate thereof) U.S. Published Application 2024 / 0228964 (the entire contents of which are herein incorporated by reference) describes the making and use of memory-like cytokine enhanced NK (m-ceNK) cells. In some aspects, m-ceNK cells may be engineered to express cytokines such as IL-2 or IL-15, to promote an inflammatory tumor microenvironment conducive to T cell recruitment and activation. In additional aspects, lysed NK-92 cells may release immune-stimulating intracellular components, such as damage-associated molecular patterns (DAMPs) and provide tumor antigens for uptake by antigen-presenting cells. In some aspects, the combination of the replication defective adenoviral vector with one or more immunostimulatory agents may improve the magnitude, quality, and durability of antigen-specific immunity. In some aspects, these agents may act individually, or in combination.
[0089] In some aspects, the combination may be co-administered. In some aspects, the combination may be administered in a temporal sequence, including but not limited to coformulation, simultaneous administration, or administration at distinct time points (e.g., a dosing regimen).
[0090] As used herein, “systemic antibodies” refers to antibodies present in the blood circulation and tissues throughout the body. As used herein, “mucosal antibodies” refers to antibodies present at mucosal surfaces.
[0091] In some aspects, the antigen-specific IgG and / or IgA may be generated in the lungs. In some aspects, the antigen-specific tissue resident T-bet+ memory B cells may be generated in the lungs, the BAL, or both.
[0092] As used herein, “IgG” refers to immunoglobulin G, the most abundant antibody isotype in serum and extracellular fluid. In some aspects, antigen-specific IgG antibodies may contribute to protection against infectious diseases or cancer by neutralizing pathogens or tumor cells, enhancing their clearance by phagocytic cells, and activating other immune effector mechanisms.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0093] As used herein, “IgA” refers to immunoglobulin A, the most abundant antibody isotype at mucosal surfaces. In some aspects, antigen-specific IgA antibodies may contribute to mucosal immunity by preventing the entry and establishment of pathogens at mucosal surfaces, particularly in the respiratory tract.
[0094] In some aspects, the method may generate systemic and mucosal antigen-specific CD8+ T cells. In some aspects, antigen-specific CD8+ T cells may contribute to protection against infectious diseases or cancer by killing infected cells or tumor cells that express the target antigen.
[0095] In some aspects, the method may generate systemic and mucosal antigen-specific B cells. In some aspects, antigen-specific B cells may contribute to protection against infectious diseases or cancer by producing antibodies and by serving as antigen-presenting cells that can activate T cells. In some aspects, the antigen-specific B cells may be generated in one or more locations selected from the group consisting of the MedLn, lungs, and / or BAL.
[0096] In some aspects, the method may generate antigen-specific tissue resident T-bet+ memory B cells. In some aspects, the cells may be generated in the lungs, the BAL, or both.
[0097] In some aspects, the present disclosure provides a method of stimulating mucosal immunity in the URT in a subject in need thereof. In some aspects, the method may include intranasally administering to the subject a replication defective adenoviral vector. In some aspects, the replication defective adenoviral vector may include a deletion in the E2b region and a nucleic acid sequence encoding one or more target antigens. In some aspects, the one or more target antigens may include infectious disease-associated proteins. In some aspects, the one or more target antigens may include cancer-associated proteins.
[0098] As used herein, “upper respiratory tract” refers to the parts of the respiratory system including the nose, nasal passages, paranasal sinuses, pharynx, and larynx. The URT may be a major site of entry for respiratory pathogens. In some aspects, the method may stimulate mucosalNant Ref. PAT.005429.W0001 RFEM Ref. 5771-117WO1 immunity in the URT by generating antigen-specific IgA and IgG antibodies in the nasal passages and other parts of the URT.
[0099] In some aspects, the one or more target antigens may include influenza virus-associated proteins. In some aspects, the method may generate IgG and IgA antibodies that bind to present influenza strains, past influenza strains, and potential pandemic influenza strains. In some aspects, the influenza strain may be PR8.
[0100] In some aspects, the present disclosure provides a method of treating influenza in a subject in need thereof. In some aspects, the method may include intranasally administering, to the subject, a replication defective adenoviral vector. In some aspects, the replication defective adenoviral vector may include a deletion in the E2b region and a nucleic acid sequence encoding one or more target antigens. In some aspects, the one or more target antigens may include influenza virus-associated proteins.
[0101] In some aspects, the one or more target antigens may include influenza virus-associated proteins. Examples of influenza virus-associated proteins include — but are not limited to — HA, NA, NP, Ml, M2, PB1, PB2, PA, & NS1.
[0102] In some aspects, the influenza virus-associated proteins may be derived from present influenza strains, past influenza strains, or potential pandemic influenza strains. Present influenza strains refer to strains of influenza virus that are currently circulating in human populations. Past influenza strains refer to strains of influenza virus that have circulated in human populations in the past but may no longer be prevalent. Potential pandemic influenza strains refer to strains of influenza virus that have the potential to cause a pandemic, i.e. , a global outbreak of disease. These strains may currently be circulating in animal populations (e.g., avian influenza viruses) or may emerge in the future through antigenic shift or other mechanisms. In some aspects, the method may generate IgG and IgA antibodies that bind to present influenza strains, past influenza strains, and potential pandemic influenza strains.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0103] In some aspects, the influenza strain may be PR8 (H1N1, A / PR / 8 / 3), which is a laboratory strain of influenza A virus that has been extensively used in influenza research. PR8 belongs to the Hl N1 subtype of influenza A vims. In some aspects, the method may generate antibodies that bind to PR8 and related strains, providing protection against these viruses.
[0104] In some aspects, the present disclosure provides a method of inhibiting contagion of influenza in a population of subjects. In some aspects, the method may include intranasally administering, to at least one subject in the population, a vaccine comprising replication defective adenoviral vector. In some aspects, the replication defective adenoviral vector may include a deletion in the E2b region and a nucleic acid sequence encoding one or more target antigens. In some aspects, the one or more target antigens may include influenza virus-associated proteins. In some aspects, the method may protect unvaccinated subjects in the population from influenza vims transmission.
[0105] Additional aspects are described below.
[0106] Aspect 1. A method of stimulating an antigen-specific immune response in a subject in need thereof, the method comprising: intranasally administering, to the subject, a replication defective adenoviral vector comprising a) a deletion in the E2b region; and b) a nucleic acid sequence encoding one or more target antigens; wherein the one or more target antigens comprise infectious disease-associated proteins or cancer-associated proteins.
[0107] Aspect 2. A method of stimulating mucosal immunity in the upper respiratory tract (URT) in a subject in need thereof, the method comprising intranasally administering to the subject a replication defective adenoviral vector comprising: a) a deletion in the E2b region and b) a nucleic acid sequence encoding one or more target antigens, wherein the one or more target antigens comprise infectious disease-associated proteins or cancer-associated proteins.
[0108] Aspect 3. A method of treating influenza in a subject in need thereof, the method comprising: intranasally administering, to the subject, a replication defective adenoviral vectorNant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 comprising a) a deletion in the E2b region and b) a nucleic acid sequence encoding one or more target antigens, wherein the one or more target antigens comprise influenza virus-associated proteins.
[0109] Aspect 4. A method of inhibiting contagion of influenza in a population of subjects, the method comprising: intranasally administering, to at least one subject in the population, a vaccine comprising a replication defective adenoviral vector comprising a) a deletion in the E2b region and b) a nucleic acid sequence encoding one or more target antigens, wherein the one or more target antigens comprise influenza virus-associated proteins.
[0110] Aspect 5. The method of any one of aspects 1 to 4, wherein the replication defective adenovirus vector further comprises a deletion in the El region.
[0111] Aspect 6. The method of any one of aspects 1 to 5, wherein the method generates systemic and mucosal antigen-specific IgG and IgA antibodies.
[0112] Aspect 7. The method of any one of aspects 1 to 6, wherein the method generates systemic and mucosal antigen-specific CD8+ T cells.
[0113] Aspect 8. The method of any one of aspects 1 to 7, wherein the method generates systemic and mucosal antigen-specific B cells.
[0114] Aspect 9. The method of aspect 8, wherein the antigen-specific B cells are generated in one or more locations selected from the group consisting of the mediastinal lymph nodes (MedLN) and / or lungs.
[0115] Aspect 10. The method of aspect 6, wherein the antigen-specific B cells are generated in the lungs.
[0116] Aspect 11. The method of aspect 10, wherein the antigen-specific B cells are isolated in bronchoalveolar lavage (BAL).
[0117] Aspect 12. The method of aspect 6, wherein the antigen-specific IgG and IgA are generated in the lungs.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0118] Aspect 13. The method of aspect 10, wherein the antigen-specific B cells are tissue resident T-bet-i- memory.
[0119] Aspect 14. The method of aspect 13, wherein the antigen-specific B cells are isolated in BAL.
[0120] Aspect 15. The method of any one of aspects 1 to 14, wherein the one or more target antigens comprise influenza virus-associated proteins, and wherein the method generates IgG and IgA antibodies that bind to present influenza strains, past influenza strains, and / or potential pandemic influenza strains.
[0121] Aspect 16. The method of aspect 15, wherein the influenza strain is PR8.
[0122] Aspect 17. The method of any one of aspects 4 to 16, wherein unvaccinated subjects in the population are protected from influenza virus transmission.EXAMPLES
[0123] While various aspects have been described herein, they have been presented by way of example only, and not limitation. Thus, the breadth and scope of the present disclosure should not be limited by any of the described exemplary aspects. Moreover, any combination of the abovedescribed elements in all possible variations thereof is encompassed by the disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.
[0124] Example 1Experimental design: Testing intranasal administration of the Ad5-NP or Ad5-HA vaccine in vivo
[0125] Intranasal administration of the Ad5-NP or Ad5-HA vaccine was evaluated in vivo in mice. Control group mice were administered 100 pL of Ad5-empty vaccine intranasally (1.0x10’9viral particles (vps) per mouse). Experimental group mice were administered 100 pL of Ad5-HA or Ad5-NP vaccine intranasally (LOxlO-9vps / mouse). Mice were evaluated at 21 days, at which time MedLn were evaluated. After 28 days, target antigens were evaluated in nasal swab, nasal wash, serum, and lungs via BAL. An overview of the experimental design is shown in FIG. 1.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0126] A MedLN gating strategy for Ad5-HA day 21 post-vaccination is shown in FIG. 2.
[0127] A MedLN gating strategy for Ad5-NP day 21 post-vaccination is shown in FIG. 3.
[0128] As shown in FIG. 4, intranasal immunization with the Ad5-NP or Ad5-HA vaccine generated antigen-specific B-cells specific to the target protein.
[0129] As shown in FIG. 5, intranasal immunization with the Ad5-NP or Ad5-HA vaccine generated systemic and mucosal antigen-specific IgG antibodies.
[0130] As shown in FIG. 6, intranasal immunization with the Ad5-NP or Ad5-HA vaccine generated systemic and mucosal antigen- speci He IgA antibodies.
[0131] FIGs. 7-9 show T-cell gating strategies for lung (FIG. 7), MedLN (FIG. 8) and BAL (FIG. 9). As shown in FIGs. 7-10, intranasal immunization with the Ad5-NP vaccine generated systemic and mucosal antigen-specific CD8 T cells.
[0132] Example 2Experimental design: Antigen-specific B-cell development following primary vaccination with Ad5-HA
[0133] Intranasal administration of the Ad5-NP or Ad5-HA vaccine was evaluated in vivo in mice. Control group mice were administered 100 pL of Ad5-empty vaccine intranasally (1.0x10'9vps / mouse). Experimental group mice were administered 100 pL of Ad5-HA or Ad5-NP vaccine intranasally (LOxlO-9vps / mouse). Mice were evaluated at days 7, 14, 21, & 28. At days 6, 14, & 21, target antigens in BAL and medLN were evaluated. At day 28, target antigens in nasal swab, nasal wash, serum, and BAL were evaluated. An overview of the experimental design is shown in FIG. 11.|0134| As shown in FIGs. 12A-C, intranasal administration of the Ad5-HA vaccine led the development of antigen-specific B-cells in the MedLN, lungs, and BAL as early as 14 days postvaccination.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 Experimental design: Characterization of antigen-specific tissue resident B-cells following primary vaccination with Ad5-HA
[0135] Intranasal administration of the Ad5-NP or Ad5-HA vaccine was evaluated in vivo in mice. Control group mice were administered 100 pL of Ad5-empty vaccine intranasally ( 1.0x1 O’9vps / mouse). Experimental group mice were administered 100 pL of Ad5-HA vaccine intranasally (l.OxlO-9vps / mouse). Vaccinated T-bet reporter mice and vaccinated B6 mice were used. Mice were evaluated at day 28 day for target antigens in BAL. An overview of the experimental design is shown in FIG. 13.
[0136] As shown in FIG. 15, intranasal administration using the Ad5 platform generated antigenspecific tissue resident T-bet-i- memory B-cells in the lungs and BAL 28 days post vaccination.
[0137] Example 3Experimental Design: Testing efficacy of vaccination i.p. vs i.n.
[0138] Intranasal administration of the Ad5-HA CA2009 (aka “CA09”) vaccine was evaluated in vivo in mice. After 33 days, target antigens were evaluated in nasal swab, MedLN, and lungs via BAL. An overview of the experimental design is shown in FIG. 16.
[0139] As shown in FIG. 17, intranasal administration with the Ad5-HA vaccine uniquely generates antigen-specific B-cells in the lungs.Experimental Design: CBA analysis of NS, BAL, and serum collected D30 post primary vaccination i.n vs i.p vs i.m
[0140] Intranasal administration of three Ad5-HA vaccines (CA2009, against H1N1; HI2022, against H1N1; and BB2018, against H1N1) was evaluated in vivo in mice, either by i.n., i.p. or i.m. After 30 days, target antigens were evaluated in nasal swab, nasal wash, serum, and lungs via BAL. An overview of the experimental design is shown in FIG. 18Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0141] As shown in FIGs. 19-22, intranasal administration with the Ad5-HA vaccine generates superior antigen-specific IgG and IgA antibodies in the lung airways compared to other routes of administration.
[0142] As shown in FIG. 19A & 19B, i.n. vaccination uniquely enhances URT IgA responses to vaccine antigen CA2009 (H1N1).
[0143] As shown in FIG. 20A & 20B, i.n. vaccination uniquely enhances URT and lung airway IgA responses to related seasonal HA WI2022 (H1N1).
[0144] As shown in FIG. 21 A & 21B, i.n. vaccination uniquely enhances URT and lung airway IgA responses to related seasonal HA BB2018 (H1N1).
[0145] As shown in FIG. 22A & 22B, i.n. vaccination uniquely enhances URT and lung airway IgA and IgG responses to distally related pandemic HA PR8-1934 (H1N1).
[0146] As shown in FIG. 23, the potential pandemic strains, or HA subtypes of influenzas A viruses, may be divided into phylogenetic Groups 1 and 2. More specifically, and as shown in FIG.23, subtypes H5, H2, and Hl are included in Group 1.
[0147] As shown in FIG. 24A & 24B and FIG. 25A & 25B, intranasal administration with the Ad5 vaccine uniquely stimulates mucosal immunity in the nasal passage (URT) and generates cross reactive IgG and IgA antibodies to present, past (including PR8), and potential pandemic strains of influenza within n the same group, Group 1. Specifically, as shown in FIG. 24A & 24B, i.n. vaccination uniquely enhances URT IgA and lung airway IgG and IgA antibody responses to avian H5N1 (VN2004).
[0148] Example 4Experimental Design: CBA comparison of nasal swabs following Ad5-HA vaccination versus infection with influenza strain CA09Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0149] Intranasal administration of the Ad5-HA (CA2009, aka “CA09”) vaccine was evaluated in vivo in mice via i.n. or i.m. After 0, 7, 14, 21, & 30 days, target antigens were evaluated using a nasal swab. An overview of the experimental design is shown in FIG. 26.
[0150] As shown in FIGs. 27-30, intranasal administration of the Ad5-HA vaccine generates superior antigen-specific IgA antibodies from the nasal cavity in comparison to mice infected with CA09.
[0151] Example 5Experimental Design: Testing the efficacy of intranasal Ad5 vaccination following PR8 exposure
[0152] Intranasal administration of the Ad5-HA (CA2009, aka “CA09”) vaccine was evaluated in vivo in mice. After 33 days, PR8 challenge was introduced. At 0, 2, 4, 6, 8, 10, 12, & 14 days post-infection, morbidity was evaluated. An overview of the experimental design is shown in FIG.31.
[0153] As shown in FIG. 32, intranasal administration with the Ad5-HA vaccine significantly protects mice from severe morbidity induced by distally related (~80 yrs) strains of influenza (PR8).
[0154] Example 6Experimental Design: Testing vaccine efficacy against live CA09 infection in the hamster model
[0155] Intranasal administration of the Ad5-HA vaccine was evaluated in vivo in hamsters. Control group hamsters were administered 100 pL of Ad5-empty vaccine intranasally. Experimental group hamsters were administered 100 pL of Ad5-HA vaccine intranasally. Serum was evaluated after 7, 14, & 21 days prior to CA09 intranasal viral infection. Hamsters were evaluated for bodyweight and morbidity daily after day 28 (day 29, day 30, day 31...) through day 42, and serum and nasal swipe were evaluated at day 33. An overview of the experimental design is shown in FIG. 33.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0156] As shown in FIGs. 34-36, hamsters vaccinated intranasally with the Ad5-HA vaccine generated antigen-specific antibodies in the nasal cavity and are protected from CA09 induced morbidity.Experimental Design: Testing transmission blocking efficacy of Ad5-HA vaccine in the hamster model
[0157] Efficacy of the Ad5-HA vaccine in blocking transmission was evaluated in vivo using a hamster model. Two groups were evaluated: Group 1 (control vehicle) and Group 2 (vaccinated). Each hamster was housed with a cage-mate throughout the study. The protocol began at day 0 (dO) with prime vaccination administered intranasally (i.n.) followed by an intranasal boost vaccination at d21. Nasal swipes were collected at d7 and between d29 and d36 to monitor viral shedding. At d26, hamsters were infected with the CA09 influenza strain and separated. After 48 hours (d28), the animals underwent a 24-hour re -pairing phase, followed by another separation at d29. Body weights were monitored from d29 through d36 to assess disease progression. The study was concluded at d55 with endpoint sample collection including blood draw, nasal wash, and lung tissue harvesting for analysis.
[0158] An overview of the experimental design is shown in FIG. 37.
[0159] As shown in FIGs. 38-42, naive unvaccinated hamsters paired with vaccinated infected hamsters are protected from viral transmission and morbidity when compared to the naive animals paired with the sham-vaccinated infected group.
[0160] Example 7Experimental Design: Ad5-vectored intranasal vaccination induces robust systemic and mucosal antigen-specific B cell, T cell and antibody responses
[0161] To investigate whether intranasal (i.n.) delivery of Ad5-vectored vaccines elicits robust adaptive immune responses in mice, 6-8 week-old C57BL / 6J (B6) mice were vaccinated via the i.n. route with IxlO9viral particles (VP) of CA09-HA Ad5 or with the empty Ad5 vector (Empty-Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 Ad5). Between day 7 (D7) and day 21 (D21) post-vaccination, draining mediastinal lymph node cells were isolated and analyzed by flow cytometry using fluorochrome-labeled tetramers of CA09HA trimers to enumerate D7 CA09HA" specific (CA09HA+) plasmablasts (PB, CD19+ / loCD138+, Figure 43A), D21 CA09HA+germinal center B cells (GCB, CD19+IgDnegCD38loPNA+, Figure 43B) and D21 CA09HA+ memory B cells (MBC, CD19+IgDnegCD38+PNA10, Figure 43B).
[0162] By D7 post-vaccination, a significant increase in both the frequency (Figure 43 A) and number (Figure 44A) of CA09HA+PB in the CA09HA-Ad5 immunized mice relative to those receiving the Empty- Ad5 vaccine was observed. Likewise, by D21 post-vaccination, the frequency (Figure 43B) and number of CA09HA+MBC (Figure 44B) and GCB (Figure 44C) were significantly elevated in animals receiving the CA09HA-Ad5 vaccine compared to the Empty-Ad5 vaccine. Similar results were seen when NP-specific B cell responses were measured in the MedLN following vaccination with the Ad5 vector carrying the influenza nucleoprotein (NP-Ad5, Figure 45A-E). Thus, mucosal i.n. administration of Ad5-based vaccines can elicit systemic PB and B cell responses in secondary lymphoid tissue.
[0163] To address whether immunization with Ad5 vaccines via the i.n. route also induced mucosal B cell responses, flow cytometry was used to enumerate CA09HA+GCB and MBC in MedLN (Figure 43B), lung (Figure 43C), and bronchial alveolar lavage (BAL, Figure 43D) samples collected between D7-D28 post-immunization from CA09HA-Ad5 and Empty- Ad5 vaccinated mice. As expected, CA09HA+MBC (Figure 44D) and GCB (Figure 44E) were detected in the MedLN. These cells were observed as early as D14, peaked by D21, and remained elevated through at least D28 post-vaccination (Figure 44D & E). Similarly, CA09HA+MBC and GCB (Figure 44F & G) were detected in the lung by D14 with the number of CA09HA+MBC continuing to increase through at least D28 (Figure 44F). CA09HA+ MBC were also detected in the BAL by D28 (Figure 44H).Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117WO1
[0164] Next, it was inquired whether vaccine-specific antibodies (Abs) could be detected at systemic and mucosal sites following i.n. delivery of the CA09HA-Ad5 or NP-Ad5 vaccines. Mice with Empty-Ad5 and either CA09HA-Ad5 or Ad5 expressing influenza nucleoprotein (NP-Ad5) were vaccinated via the i.n. route. On D28 serum was collected, which contains the systemic Abs, BAL, which contains Abs present in the lung airways and lower respiratory tract (URT), nasal wash (NW), which contains Ab present in the upper respiratory tract ((URT), oral pharyngeal and nasal cavities) and nasal swipes (NS), which contain the Abs present at the interface between the nasal cavity and the outside environment. Samples were incubated with cytometric beads arrayed (CBA) with recombinant flu proteins. Binding of serum polyclonal Ab to CA09HA antigen was detected using fluorochrome-labeled secondary Abs specific for murine IgG or IgA. Consistent with the detectable systemic B cell response in the MedLN, CA09HA-specific IgG was detected in serum as well as NS, NW, and BAL samples (Figure 441). Notably, CA09HA-specific IgA responses in the mucosal BAL, NW, and NS samples were also significantly elevated in the CA09HA-Ad5 vaccinated animals compared to Empty-Ad5 vaccinated mice (Figure 44J). Similar results were observed in mice vaccinated with NP-Ad5 (Figure 45F-G).
[0165] Since i.n. vaccination with the Ad5-vectored vaccines elicited both mucosal and systemic B cell and Ab responses, it was predicted that the vaccines should also induce systemic and mucosal T cell responses. Accordingly, B6 mice were immunized i.n. with the NP-Ad5 or Empty-Ad5 vaccines and T cell NP tetramers (H-2Db NP366-374) were used to monitor the frequencies (Figure 49A-C) and numbers (Figure 49D-F) of NP+CD8+T cells in the MedLN (Figure 49A & D), lung (Figure 49B & E), and BAL (Figure 45C & F) between D7-28 post-immunization. Similar to the vaccine-elicited B cell response, the NP+CD8 T response was observed by D14 in both the MedLN and mucosal sites and was maintained for at least 28 days post-vaccination. Moreover, the frequencies (D21, Figure 49A-C) and absolute numbers (DI4-D28. Figure 49D-F) of NP-specihc CD8+T cells were significantly greater in all three tissues of the NP-Ad5Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 vaccinated animals compared to Ad5-empty vaccinated mice. Taken together, these data show that i.n. administration of either the CA09HA-Ad5 or NP-Ad5 vaccine elicits systemic and respiratory tract cellular and humoral immunity.
[0166] Example 8Experimental Design: Intranasal immunization with Ad5-vectored vaccines promotes accumulation of antigen-specific lung tissue and airway residing B cells
[0167] Natural infection with influenza induces a population of T-bet-expressing, nonrecirculating, lung resident MBC (B resident memory cells or BRM) that are localized within the lung parenchyma and airways. B cell intrinsic expression of T-bet is required for the “effector” lung BRM to differentiate rapidly in situ into secondary PB that provide local protective immunity following challenge infection. Importantly, these T-bet+ effector MBC were not induced when influenza virus was administered intraperitoneally (i.p.), suggesting that establishment of this protective MBC compartment requires local antigen delivery. To test whether i.n. delivery of the HA-Ad5 vaccine can generate the effector T-bet + BRM compartment, the CA09HA-Ad5 vaccine was administered i.n. to either B6 mice or Tbx21-ZsGreen mice that express the fluorescent reporter ZsGreen under the control of the T-bet gene (Tbx21) promoter. Flow cytometry was used to detect CA09HA+MBC expressing the T-bet reporter in the lung and BAL of D28 vaccinated animals. Significantly elevated frequencies (Figure 46A & B) and absolute numbers (Figure 46C) of T-bet+HA tetramer-binding memory B cells were observed in the lungs 28 days after vaccination. Similarly, Tbx21 reporter expressing MBC were easily detected and significantly elevated in the BAL of i.n. vaccinated mice (Figure 46D-F). Moreover, 75-85% of all CA09HA-specific MBC found in lung (Figure 46B) and BAL (Figure 46E) expressed the Tbx2I reporter. Thus, the majority of mucosal MBC elicited by the i.n. administered vaccine were likely resident in the respiratory tract and exhibited an effector BRM phenotype.
[0168] Example 9Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 Experimental Design: Mucosal, but not systemic, administration of the Ad5 vectored immunogen induces antigen-specific lung memory B and T cells and promotes mucosal antibody responses
[0169] Intransal immunization with an Ad5-vectored vaccine induced systemic as well as local mucosal B cell immune responses. Given these results, it was predicted that i.n. vaccination with an Ad5-vectored vaccine should also generate resident memory CD8 T cells (CD8 TRM), which are known to support local rapid killing of virus infected cells. To test this, 6-8-week-old B6 mice were immunized with IxlO9VP of Empty-Ad5 given i.n. or NP-Ad5 given either i.n. or i.p. and then flow cytometry (Figure 48A & B) was used to enumerate the NP-specific (H2KD(b)NP366-374) CD8+ T cell subsets in medLN, which drains the peritoneal cavity and the lung. Few NP+ TRM (CD103+CD69+, Figure 47 A) or NP+memory (CXCR6+CXCR3 , Figure 47B) CD8 T cell were identified in the medLN at this timepoint, regardless of whether the animals were immunized via the i.n. route or i.p. route. However, NP+ effector / memory (CXCR6 CXCR3+) CD8 T cells were elevated in the medLN of the NP-Ad5 immunized mice (Figure 47 C), with the largest expansion seen following i.n. immunization. Consistent with prior reports showing that lung CD8 TRM are generated following i.n. infection or i.n. vaccination, a large population of CD8+lung TRM was identified only after i.n. immunization (Figure 47D). Similarly, the NP+CXCR6+CXCR3" memory CD8 T cells were only expanded in the lungs of i.n. immunized mice (Figure 47E) while NP+effector memory CD8 T cells were observed in the lungs of animals immunized by either route (Figure 47F). Therefore, the data showed that development of the CD8 lung TRM population is highly dependent on the NP-Ad5 vector being delivered intranasally.
[0170] To address whether the establishment of the lung B cell and mucosal AB response was dependent on i.n. delivery of CA09HA Ad5, 6-8-week-old B6 mice were immunized with IxlO9VP of Empty-Ad5 given i.n. or CA09HA Ad5 given either i.n. or i.p. On D30 post-immunization, lung, MedLN, serum, BAL, and NS samples were collected for analysis. CA09HA+ GCB and MBC in lung and MedLN (Figure 48C-D) were detected using flow cytometry and CA09HA-Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 specific IgG and IgA Abs in serum, BAL and NS were measured using CBA. Not surprisingly, the medLN harbored CA09HA-specific MBC and GCB following vaccination (Figure 47G & H) and there was no significant difference in the number of medLN CA09HA+MBC and GCB in the i.n. and i.p. vaccinated groups. By contrast, CA09HA+MBC and GCB were only detected in the lungs of animals vaccinated via the i.n. route (Figure 471 & J). Thus, i.p. delivery of the vaccine was not sufficient to support establishment of lung residing MBC and GCB populations.
[0171] Both routes of vaccine administration induced a robust systemic serum CA09HA-specific IgG Ab response (Figure 47K) and there was no significant difference between the two vaccinated groups of mice. Likewise, CA09HA-specific IgG Abs were detected in the BAL (Figure 47L) and NS (Figure 47M) samples from both vaccinated groups. However, the levels of CA09HA-specific IgG in BAL and NS samples were modestly but significantly higher in the i.n. vaccinated mice compared to the i.p. vaccinated animals (Figure 47L & M). Both vaccination routes also generated CA09HA-specific IgA responses in serum (Figure 47N) and BAL (Figure 470), but again the response was significantly elevated in animals vaccinated via the i.n. route. Strikingly, CA09HA-specific IgA in nasal secretions from the NS sample was only detected in the i.n. vaccinated mice with anti-CA09HA IgA levels in i.p. vaccinated mice at background (Figure 47P). Thus, only mucosal delivery of the vaccine elicited production of secretory IgA present at the physiologic site of influenza virus entry located at the interface between the nose and the environment.
[0172] Given that a single systemic immunization with the CA09HA-Ad5 vaccine was unable to induce an URT IgA response, it was inquired whether boosting systemically could elicit IgA in nasal secretions. Mice were therefore primed with CA98HA-Ad5 vaccine given either i.n. or i.p. and administered a homologous boost (i.n. -i.n. or i.p-i.p.) on D30 post primary immunization. The URT IgG and IgA CA09HA-specific Ab response was assessed in the NS on 5 days post-boost in both groups of mice (Figure 47Q & R). Again, animals that were primed and boosted via the i.n.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 route had significantly increased levels of IgG present in the NS relative to the i.p.-i.p. group (Figure 47Q). Moreover, CA09HA-specific IgA Abs in NS were only detected the i.n.-i.n. group (Figure 47R). Taken together, the data suggests that local antigen exposure is needed to establish the lung resident memory B and T cells and the URT Ab response.
[0173] Example 10Experimental Design: Vaccination with CA09HA-Ad5 via the i.n. route uniquely supports a broadly reactive Ab response to influeza HA antigens
[0174] Infection of mice with influenza vims induces a broadly reactive HA response. To address whether a broadly reactive Ab response was elicited following immunization with the CA09HA-Ad5 vector via the i.n. route, the humoral immune response in 6-8 week-old B6 animals vaccinated i.n. was compared to animals vaccinated via the i.m. route, used for most U.S. licensed human vaccines. For a negative control, mice were immunized i.n. with Empty-Ad5 and for a positive control, mice were infected i.n. with a non-lethal dose (500 PFU) of the non-mouse adapted CA09 influenza vims strain. Nasal swipe samples were collected weekly from immunized and infected animals. On D30 animals were euthanized and semm, NW, and BAL samples were collected (Figure 50A). To assess the breadth of the humoral immune response, samples were analyzed using the CBA platform arrayed with a panel of HA antigens, including H1,_HA, and H3_HA antigens derived from different seasonal / pandemic viral strains as well as H2, _HA, and H5_HA antigens derived from avian viral strains.
[0175] Mice vaccinated with CA09HA-Ad5 or infected with CA09 vims developed comparable levels of semm Hl_HACA09-specific IgG (Figure 50B) and this response was several orders of magnitude higher than seen in semm of animals immunized with Empty-Ad5. Consistent with earlier experiments, i.n. vaccinated animals exhibited superior CA09HA-specific IgG (Figure 51 A) and IgA (Figure 50C) responses in the BAL when compared to i.m. vaccinated mice. In fact, the IgA BAL response in the i.n. vaccinated animals was equivalent to that seen in the infectedNant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 mice (Figure 50C), indicating that i.n. delivery of CA09HA-Ad5 was as effective as influenza infection in eliciting a lung mucosal IgA response. Similar to a prior experiment showing minimal IgA responses in the NW from i.p. vaccinated animals, the CA09HA-specific IgA (Figure 50D) and IgG (Figure 5 IB) response in the NW of i.m. vaccinated mice was not substantively higher than that detected in the Empty-Ad5 immunized mice. By contrast, the i.n. vaccinated mice made a robust IgG (Figure 51B) and IgA (Figure 50D) response in the URT that was comparable or even greater than that seen in the CA09-infected mice. In addition, the CA09HA Ab response in the NS, which captures Ab at the interface of the nasal cavity with the environment, was largely limited to i.n. vaccinated mice (Figure 51C, Figure 47E). While low levels of IgG CA09HA-specific Abs were detected in the NS samples (Figure 51C), the major isotype present in that site was IgA (Figure 47E). Consistent with published data showing that replication of non-mouse adapted flu vims in the URT of wild-type mice is limited, particularly in the nasal cavity and turbinates
[0023] , CA09HA-specific IgA was not observed in NS samples from infected mice and was exclusively detected in the i.n. vaccinated animals (Figure 47E).
[0176] It was interrogated whether the IgG and IgA Abs elicited following CA09HA-Ad5 vaccination or infection exhibited binding to HA antigens from seasonally drifted strains of the 2009 Hl_CA09HA vims, including H1_BB18HA (Figure 50F-I, Figure 51D-F), which circulated in 2018, and the H1_WI22HA (Figure 50J-M, Figure 51G-I), which circulated in 2022. IgG that exhibited reactivity for these related H1_HA antigens were present in serum (Figure 50F, 50J). Likewise, BAL IgA (Figure 50G, 50K) and IgG (Figure 5 ID, 51G) capable of recognizing the related Hl HA antigens were easily detected in the vaccinated and infected mice, although the response was significantly lower in the i.m. vaccinated mice relative to the other groups. However, IgA (Figure 50H, 50L) and IgG (Figure 51E, 51H) Abs in the NW samples that bound the drifted HA antigens were not significantly different between the negative control Empty-Ad vaccinated animals in mice vaccinated i.m. with CA09HA-Ad5. By contrast, the i.n. vaccinated and flu-Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 infected mice generated equivalent and high levels of NW IgA (Figure 50H, 50L) and IgG (Figure 5 IE, 51H) that bound the drifted H1_HA antigens. Moreover, and consistent with the poor IgA HA-specific response in the NW of i.m. vaccinated mice, minimal IgA (Figure 501, 50M) and IgG (Figure 51F, 511) reactivity to related Hl-HA proteins was observed in the NS samples from the i.m. vaccinated group. However, IgA binding to the seasonal-drifted H1_HA antigens was easily and uniquely detected in the NS samples from i.n. vaccinated animals (Figure 501, 50M).
[0177] Given these results, it was inquired whether i.n. vaccination with CA09HA-Ad5 elicited antibody responses that could bind to more distantly related HA proteins. First, it was examined whether the antibodies elicited in response to vaccination or infection with the CA09HA antigen, which was isolated from influenza that first circulated in 2009, recognized H1_A / PR8 / 34HA (PR8 / 34HA) antigen, which was derived from influenza circulating in 1934. Mice vaccinated via the i.m. route did not make detectable PR8 / 34HA binding IgG in serum (Figure 50N) BAL, NW, or NS samples (Figure 51J-L). PR8 / 34HA-binding IgA could not be detected in BAL (Figure 500), NW (Figure 50P), or NS samples (Figure 50Q) isolated from the i.m. vaccinated mice. However, mice infected or vaccinated via the i.n. route generated PR8 / 34HA-binding IgG in serum (Figure 50N) as well as PR8 / 34HA-binding IgA (Figure 50O-P) and IgG (Figure 51J-K) in BAL and NW. Again, only mice vaccinated via the i.n. route generated detectable NS IgA that recognized the evolutionarily distant PR8HA antigen (Figure 50Q).
[0178] While the IgA and IgG responses generated in response to i.n. vaccination or infection were broadly reactive against even this less conserved Group 1 H1_HA antigen, the broad responsiveness did not extend to Group 2 HA antigens, like H3 DW21HA (Figure 55A-G). However, antibodies from both the i.n. vaccinated and CA09-infected mice did exhibit detectable binding to other more distant Group 1 HA antigens, including those of avian origin like H2_NL99HA (Figure 55H-N) and H5_VN04HA (Figure 550-U). In particular, mice vaccinated with CA09HA-Ad5 via the i.n. but not the i.p. route generated IgA in the LRT (BAL, Figure 551,Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 55P) and URT (NW, Figure 55J, 55Q) that exhibited easily detectable binding to the H2_HA and H5_HA antigens derived from avian influenza isolates. Taken together, these data show that i.n. vaccination with CA09HA-Ad5 induces a broadly reactive mucosal response that resembles the response seen after infection and is of greater magnitude and breadth than that seen following i.m. vaccination. In addition, only i.n. vaccination elicits a broadly reactive IgA Ab response in the URT.
[0179] Example 11Experimental Design: Intranasal CA09HA-Ad5 vaccination facilitates viral clearance and lung protection following infection with an evolutionarily distant Hl virus strain.
[0180] Given that Hl_PR8 / 34HA-reactive IgA Abs could be detected in the URT of mice vaccinated i.n. but not i.m. with CA09HA-Ad5, it was predicted that the i.n. vaccinated mice would be better protected than i.m. vaccinated mice following PR8 / 34 virus challenge. To test this, 6-8 week-old B6 mice were primed i.n. or i.m. with CA09HA-Ad5 or Empty-Ad5 and then boosted (D30) via the same route (i.n. / i.n. ori.m. / i.m., Figure 52A). Five days post-boost, NS samples were collected, and the mice were then challenged with high dose (6500 PFU) PR8 / 34 virus that typically causes 25-28% body weight loss in mice. The infected animals were weighed daily through D15 post-challenge. On D22 post-challenge lung tissue was harvested, inflated and processed for histopathology analysis (H&E and Sirius Red staining). A separate cohort of animals was sacrificed on D3 post-challenge to measure replicating virus in the lungs and NW using the viral foci assay (VFA) (Figure 52A).
[0181] Consistent with our prior data, IgA exhibiting reactivity for the vaccine C A09HA antigen (Figure 52B) as well as the distantly-related PR8 / 34HA antigen (Figure 52C) was only detected in NS samples from the i.n. vaccinated mice and was not found in the NS samples from the i.m. vaccinated animals. Consistent with the more broadly reactive mucosal Ab response in the i.n. vaccinated animals, we observed significantly less replicating PR8 / 34 virus in both the URT (NW,1Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 Figure 52D) and LRT (lung, Figure 52E) of the mice vaccinated i.n. with CA09HA-Ad5. At D3 post-challenge, the viral loads in the NW and lungs of the i.m. vaccinated animals were not significantly different than that observed in animals immunized with Empty -Ad5 (Figure 52D & E). The i.n. vaccination appeared to promote more rapid clearance of the distantly related Hl_PR / 34 virus throughout the entire respiratory tract. The i.n. vaccinated animals lost the least amount of weight and recovered more rapidly than mice immunized i.m. with CA09HA-Ad5 or i.n. with Empty-Ad5 (Figure 52F). To address whether the more rapid viral clearance seen following i.n. vaccination resulted in reduced lung damage, a blinded histopathology analysis of D22 post-challenge infection lung tissue sections (Figure 52G & H) was performed. Individual scores for lung fibrosis (Ashcroft score, Figure 521) and lung inflammation / damage in the airways (Figure 52J), alveoli (Figure 52K), and vascular (Figure 52L) compartments were determined, and an overall score (Figure 52M) was calculated.
[0182] The findings showed that the lungs of Empty- Ad5 vaccinated animals displayed marked fibrosis (Figure 521), damage and cellular infiltration (Figure 52J-M) at 22 days post-challenge. While airway infiltration was reduced in i.m. vaccinated animals relative to the Empty-Ad5 controls (Figure 52J), there was no difference in Ashcroft, alveolar, and vascular histopathology scores (Figure 521, 6K, 6L) between i.m. CA09HA-Ad5 vaccinated and the Empty- Ad5 vaccinated mice. In fact, only the i.n. CA09HA-Ad5 vaccinated mice exhibited significantly reduced lung fibrosis and inflammation (Figure 52I-L) and reduced overall pathology scores (Figure 52M). Therefore, rapid viral clearance, reduced morbidity, and prevention of lung damage following challenge with an evolutionarily distant Hl influenza virus was supported by delivery of the CA09HA-Ad5 vaccine via the i.n. but not the i.m. route.
[0183] Example 12Experimental Design: Intranasal vaccination with CA09HA-Ad5 supports broadly reactive antibody responses and accelerates viral clearance in hamsters.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01
[0184] Intranasal immunization of laboratory mice with the CA09HA-Ad5 vaccine promoted rapid viral clearance and decreased morbidity and lung damage following experimental infection with a distantly related influenza virus. However, it is understood that human strains of influenza virus do not efficiently infect the URT of mice and that the URT of mice is anatomically distinct from humans. By contrast, the upper respiratory tract of Golden Syrian hamsters (GS hamsters) — a species that diverged from mice several million years ago — is more similar to humans compared to mice. Moreover, GS hamsters are naturally susceptible to non-adapted human influenza A viruses, including recent H1N1 and H3N2 strains. High titers of virus can be recovered from hamster nasal turbinates and washes. Therefore, it was inquired whether i.n. delivery of the CA09HA vaccine in hamsters also uniquely supported the development of more broadly reactive mucosal Ab responses. 9-11 week-old GS hamsters were immunized i.n. or i.m. with IxlO9VP of CA09HA-Ad5 and control hamsters were immunized with Empty- Ad5 delivered via the i.n. route. All animals were given a homologous boost on D30 (i.m. / i.m., i.n. / i.n.) and then challenged i.n. with CA09 virus on D36. Blood and NS samples were collected longitudinally at multiple points and NW and lung tissue was collected on D4 post-challenge infection (Figure 53A).
[0185] Consistent with the mouse data, both i.n. and i.m. vaccination elicited CA09HA-binding IgG in serum by D21 post-prime (Figure 53B). While both routes of vaccination supported the development of a systemic antibody response, i.n. vaccination induced significantly higher levels of CA09HA-specific IgG in the serum compared to i.m. vaccination. This remained true on D6 post-boost (Figure 53C), indicating that i.n. vaccination of hamsters with an Ad5 vector effectively supported systemic humoral immune responses. Moreover, only vaccination via the i.n. route elicited CA09HA-binding IgG (Figure 53D & E) and IgA (Figure 53F & G) Abs in NS samples. These antibodies could be detected as early as D7 post-primary vaccination (Figure 53D, 7F) and increased following the i.n. boost (Figure 53E, 7G). Thus, i.n. immunization, but not systemic delivery of the vaccine, induced robust URT immunity.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117WO1
[0186] Next, we evaluated whether i.n. delivery of the CA09HA-Ad5 vaccine selectively induced a broadly reactive response to H1_HA antigens from recent circulating strains and historical isolates. Similar to what we previously observed in mice, IgG and IgA responses to H1_BB18HA (Figure 54A-F), H1_WI22HA (Figure 54G-L) and H1_PR8 / 34HA (Figure 54M-R) in serum and NS samples were predominantly seen in SG hamsters vaccinated via the i.n. route. This was particularly evident when IgA (Figure 54E & F, 54K & L, 54Q & R) and IgG (Figure 54C & D, 541 & J, 540 & P) HA-binding Abs were measured in the NS samples. Moreover, and similar to what we observed in mice, boosting systemically via the i.m. route was not sufficient to initiate a local mucosal antibody response. These data therefore suggested that URT mucosal humoral immunity in hamsters also requires local Ag delivery.
[0187] Given the superior mucosal immune response in the i.n. vaccinated SG hamsters, it was predicted that these animals would be better protected following challenge infection. To test this, six days following the i.n. or i.m. boost, hamsters were challenged via the i.n. route with IxlO8PFU CA09 influenza. A subset of animals was euthanized on D4 post-challenge to assess viral burden in the lungs and NW, while the remaining animals were monitored longitudinally for viral shedding in NS samples (Figure 53A). Consistent with robust pre-existing systemic immunity, both groups of vaccinated hamsters exhibited lower levels of infectious vims in the lungs at 4 dpi compared to the Empty-Ad5 vaccinated hamsters (Figure 53H). However, while 100% of the i.n. vaccinated animals had no detectable vims in the lung at D4 post-challenge, vims was still detected in the lung homogenates from 40% of the i.m. vaccinated animals. Moreover, at D4 post-challenge infection, the viral load in the NW of the i.m. vaccinated mice was indistinguishable from the animals vaccinated with Empty-Ad5 (Figure 531). By contrast, no infectious vims could be detected in the NW of the CA09HA i.n. vaccinated animals on D4 post-challenge (Figure 531).
[0188] Using a more sensitive, PCR-based assay to detect viral N (nucleoprotein) RNA in the NS samples, equivalent levels of vims were observed at 1 hr post-infection (Figure 53J). However,Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 by 24 hrs post-challenge, viral N RNA levels were significantly lower in NS samples from the i.n. vaccinated and challenged hamsters (Figure 53J) and by 48 hrs post-challenge, no viral N RNA could be detected in NS samples from the i.n. vaccinated animals (Figure 53J). Indeed, viral RNA in nasal secretions from the i.n. vaccinated hamsters undetectable almost a full day earlier than the i.m. vaccinated animals.
[0189] Since virus clearance in both the URT and LRT was significantly accelerated in the i.n. vaccinated hamsters, it was predicted that the viral load in the i.n. vaccinated animals might be sufficient to elicit a humoral immune response to the challenge vims. To address this, the humoral immune response to vims proteins was measured, including NP and NS1, that were not present in the vaccine. Hamsters vaccinated with Empty-Ad5 or i.m. vaccinated with CA09HA-Ad5 made easily detectable semm anti-NP (Figure 53K) and anti-NSl (Figure 53L) IgG responses, indicating that the hamsters in both groups had been productively infected with Hl_CA09 vims. By contrast, i.n. vaccinated animals made a low to undetectable NS1 and NP IgG response following challenge infection (Figure 53K & L), indicating that viral load in these animals was too low to trigger an adaptive B cell response. Taken together the data show that delivery of the Ad5-vectored vaccine via the intranasal route elicits a strong systemic response and uniquely supports the establishment of URT and LRT B cells and T cell responses. Moreover, i.n. delivery of the vaccine elicited a more broadly reactive IgA and IgG Ab response within the URT, particularly at the site of viral entry. This local mucosal delivery of the vaccine accelerated viral clearance following challenge infection and resulted in less lung damage, even after challenge with a divergent strain of vims. Given that the protective response elicited by the i.n. delivered vaccine was conserved across mice and hamsters that diverged in evolution millions of years ago, engagement of the mucosal immune response through local antigen delivery may be one key to developing vaccines that induce broadly reactive responses.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117WO1
[0190] The foregoing description has been presented for purposes of illustration and description. This description is not intended to limit the invention to the precise form disclosed. Persons of ordinary skill in the art will appreciate that modifications and substitutions of the basic inventive description may be made.
Claims
Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 CLAIMSWhat is claimed is:
1. A method of stimulating an antigen-specific immune response in a subject in need thereof, the method comprising: intranasally administering, to the subject, a replication defective adenoviral vector comprising a) a deletion in the E2b region; and b) a nucleic acid sequence encoding one or more target antigens; wherein the one or more target antigens comprise infectious disease-associated proteins or cancer-associated proteins.
2. A method of stimulating mucosal immunity in the upper respiratory tract (URT) in a subject in need thereof, the method comprising intranasally administering to the subject a replication defective adenoviral vector comprising: a) a deletion in the E2b region and b) a nucleic acid sequence encoding one or more target antigens, wherein the one or more target antigens comprise infectious disease-associated proteins or cancer-associated proteins.
3. A method of treating influenza in a subject in need thereof, the method comprising: intranasally administering, to the subject, a replication defective adenoviral vector comprising a) a deletion in the E2b region and b) a nucleic acid sequence encoding one or more target antigens, wherein the one or more target antigens comprise influenza virus-associated proteins.
4. A method of inhibiting contagion of influenza in a population of subjects, the method comprising: intranasally administering, to at least one subject in the population, a vaccine comprising a replication defective adenoviral vector comprising a) a deletion in the E2b region and b) a nucleic acid sequence encoding one or more target antigens, wherein the one or more target antigens comprise influenza virus-associated proteins.
5. The method of any one of claims 1 to 4, wherein the replication defective adenovirus vector further comprises a deletion in the El region.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 6. The method of any one of claims 1 to 5, wherein the method generates systemic and mucosal antigen-specific IgG and IgA antibodies.
7. The method of any one of claims 1 to 6, wherein the method generates systemic and mucosal antigen-specific CD8+ T cells.
8. The method of any one of claims 1 to 7, wherein the method generates systemic and mucosal antigen-specific B cells.
9. The method of claim 8, wherein the antigen-specific B cells are generated in one or more locations selected from the group consisting of the mediastinal lymph nodes (MedLN) and / or lungs.
10. The method of claim 6, wherein the antigen-specific B cells are generated in the lungs.
11. The method of claim 10, wherein the antigen-specific B cells are isolated in bronchoalveolar lavage (BAL).
12. The method of claim 6, wherein the antigen-specific IgG and IgA are generated in the lungs.
13. The method of claim 10, wherein the antigen-specific B cells are tissue resident T-beH-memory.
14. The method of claim 13, wherein the antigen-specific B cells are isolated in BAL.
15. The method of any one of claims 1 to 14, wherein the one or more target antigens comprise influenza virus-associated proteins, and wherein the method generates IgG and IgA antibodies that bind to present influenza strains, past influenza strains, and / or potential pandemic influenza strains.
16. The method of claim 15, wherein the influenza strain is PR8.Nant Ref. PAT.005429.W0001 RFEM Ref. 5771-117W01 17. The method of any one of claims 4 to 16, wherein unvaccinated subjects in the population are protected from influenza virus transmission.
